Skip to main content

Featured

5 Things to Know Today: TSX Recap, Oil Eases, Loonie Under Pressure & Alberta's Pipeline Announcement (July 3, 2026)

  Friday, July 3, 2026 Here's what's moving markets and your money this morning — from Bay Street to the pumps to Ottawa. 1. TSX gains as investors digest a mixed session The S&P/TSX Composite closed up 0.31% on Thursday at 34,966.67 points (+109.68), its first full trading day back after the Canada Day holiday. Financials were mixed — Brookfield edged higher while TD Bank slipped nearly 1% — but mining stocks got a lift as gold prices ticked up, with Barrick and Franco-Nevada both up more than 3%. Shopify was the standout, jumping over 5% after settling a dispute with Shopline. 2. Oil prices ease as Iran-US talks continue in Doha Crude prices pulled back further and are now trading closer to pre-conflict levels after another round of indirect US-Iran talks in Doha, even though the sides didn't reach a breakthrough. That's welcome news for anyone filling up this long weekend, and it's also easing some of the energy-driven inflation pressure that's been compl...
Post a Comment
Read more

article

Labels

Alzheimer’s vaccines get a boost from new drug approval

 

After decades of disappointment and controversy, the field of Alzheimer’s disease research has finally seen a breakthrough with the approval of the first drug that targets the underlying pathology of the condition. 

Aducanumab, a monoclonal antibody that clears amyloid plaques from the brain, was granted accelerated approval by the US Food and Drug Administration in June 2021, despite mixed results from clinical trials and objections from some experts. 

The drug’s approval has rekindled interest in other therapeutic approaches that aim to prevent or slow down the progression of Alzheimer’s, such as vaccines that stimulate the immune system to attack amyloid or tau, another protein that accumulates in the brains of people with the disease. 

Several vaccine candidates are currently in various stages of development and testing, and some researchers are optimistic that they could offer a more effective and convenient way to treat Alzheimer’s than infusions of antibodies.


Labels:

Comments

Post a Comment